No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine

Clinical and Experimental Rheumatology

Volumn 35, Issue 5, 2017, Pages 857-859

  Friedman, Deborah ^a   Lovig, Leif ^b   Halushka, Marc ^c   Clancy, Robert M ^d   Izmirly, Peter M ^d   Buyon, Jill P ^d  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Children's and Women's Physicians of Westchester LLP   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart block; Hydroxychloroquine; Lupus; Pregnancy

Indexed keywords

DEXAMETHASONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; RO ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; CLINICAL ARTICLE; COMPLETE HEART BLOCK; CONGENITAL HEART BLOCK; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; ENDOCARDIAL FIBROELASTOSIS; FEMALE; FETUS; FETUS ECHOGRAPHY; GESTATIONAL AGE; HEART ATRIOVENTRICULAR NODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MATERNAL EXPOSURE; PREGNANCY TERMINATION; PRIORITY JOURNAL; SINUS RHYTHM; SYSTEMIC LUPUS ERYTHEMATOSUS; TRICUSPID VALVE REGURGITATION; AUTOPSY; CHEMICALLY INDUCED; DRUG EFFECTS; FETUS HEART; HEART BLOCK; HEART DISEASE; IMMUNOLOGY; PATHOLOGY; PREGNANCY; RISK FACTOR; THERAPEUTIC ABORTION; TREATMENT OUTCOME;

ABORTION, THERAPEUTIC; ADULT; ANTIRHEUMATIC AGENTS; AUTOPSY; CARDIOTOXICITY; FEMALE; FETAL HEART; HEART BLOCK; HEART DISEASES; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; RISK FACTORS; TREATMENT OUTCOME;

EID: 85029741777     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. BRUCATO A, FRASSI M, FRANCESCHINI F et al.: Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-35
2. BUYON JP, IZMIRLY PM: Neonatal lupus: clinical spectrum, biomarkers, and approach to treatment. In: LAHITA R, TSOKOS G, BUYON J, KOIKE T (Eds.): Systemic lupus erythematosus. 5th ed., Amsterdam, Netherlands, Elsevier 2016: 541-72
3. LLANOS C, IZMIRLY PM, KATHOLI M et al.: Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/ fetal risk factors. Arthritis Rheum 2009; 60: 3091-97
4. IZMIRLY PM, SAXENA A, KIM MY et al.: Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927-35
5. LLANOS C, FRIEDMAN DM, SAXENA A et al.: Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology 2012; 51: 1086-92
6. CLANCY RM, ALVAREZ D, KOMISSAROVA E, BARRAT FJ, SWARTZ J, BUYON JP: Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol 2010; 184: 2148-55
7. IZMIRLY PM, KIM MY, LLANOS C et al.: Evaluation of the risk of anti-SSA/Ro-SSB/ La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69: 1827-30
8. IZMIRLY PM, COSTEDOAT-CHALUMEAU N, PISONI CN et al.: Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82
9. COSTEDOAT-CHALUMEAU N, AMOURA Z, DUHAUT P et al.: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirtythree cases compared with a control group. Arthritis Rheum 2003; 48: 3207-11
10. CLOWSE ME, MAGDER L, WITTER F, PETRI M: Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640-47
11. COSTEDOAT-CHALUMEAU N, HULOT JS, AMOURA Z et al.: Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 2007; 107: 73-80
12. JOYCE E, FABRE A, MAHON N: Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2013; 2: 77-83
13. TONNESMANN E, KANDOLF R, LEWALTER T: Chloroquine cardiomyopathy-a review of the literature. Immunopharmacol Immunotoxicol 2013; 35: 434-42
14. SOONG TR, BAROUCH LA, CHAMPION HC, WIGLEY FM, HALUSHKA MK: New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy-a report of 2 cases. Hum Pathol 2007; 38: 1858-63
15. NANCE JW, Jr., CRANE GM, HALUSHKA MK, FISHMAN EK, ZIMMERMAN SL: Myocardial calcifications: pathophysiology, etiologies, differential diagnoses, and imaging findings. J Cardiovasc Comput Tomogr 2015; 9: 58-67